Goldman Sachs’s AstraZeneca AZN Stock Holding History

Goldman Sachs’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.9M	Buy	176,900 +175,000	+9,211%	+$33.7M	﹤0.01%	1886
2025 Q4	$349K	Hold	1,900	–	–	﹤0.01%	5790
2025 Q3	$292K	Hold	1,900	–	–	﹤0.01%	5764
2025 Q2	$266K	Hold	1,900	–	–	﹤0.01%	5510
2025 Q1	$279K	Sell	1,900 -18,050	-90%	-$2.61M	﹤0.01%	5497
2024 Q4	$2.61M	Buy	+19,950	New	+$2.79M	﹤0.01%	4058
2024 Q3	–	Sell	-35,000	Closed	-$5.46M	–	5809
2024 Q2	$5.46M	Buy	35,000 +17,500	+100%	+$2.63M	﹤0.01%	3065
2024 Q1	$2.37M	Sell	17,500 -150,500	-90%	-$19.9M	﹤0.01%	3750
2023 Q4	$22.6M	Hold	168,000	–	–	﹤0.01%	1779
2023 Q3	$22.8M	Hold	168,000	–	–	﹤0.01%	1676
2023 Q2	$24M	Hold	168,000	–	–	0.01%	1694
2023 Q1	$23.3M	Buy	168,000 +49,000	+41%	+$6.59M	0.01%	1682
2022 Q4	$16.1M	Hold	119,000	–	–	﹤0.01%	2146
2022 Q3	$13.1M	Hold	119,000	–	–	﹤0.01%	2261
2022 Q2	$15.7M	Hold	119,000	–	–	﹤0.01%	2099
2022 Q1	$15.8M	Buy	119,000 +53,068	+80%	+$6.36M	﹤0.01%	2257
2021 Q4	$7.68M	Hold	65,932	–	–	﹤0.01%	3003
2021 Q3	$7.92M	Buy	65,932 +31,282	+90%	+$3.64M	﹤0.01%	2945
2021 Q2	$4.15M	Buy	+34,650	New	+$3.8M	﹤0.01%	3507
2021 Q1	–	Sell	-25,000	Closed	-$2.5M	–	6073
2020 Q4	$2.5M	Hold	25,000	–	–	﹤0.01%	3561
2020 Q3	$2.74M	Buy	25,000 +8,550	+52%	+$951K	﹤0.01%	3348
2020 Q2	$1.74M	Buy	+16,450	New	+$1.7M	﹤0.01%	3561
2019 Q4	–	Sell	-50,000	Closed	-$4.46M	–	5205
2019 Q3	$4.46M	Sell	50,000 -152,500	-75%	-$13.2M	﹤0.01%	2944
2019 Q2	$16.7M	Buy	+202,500	New	+$15.9M	﹤0.01%	1989
2019 Q1	–	Sell	-3,750	Closed	-$285K	–	5112
2018 Q4	$285K	Hold	3,750	–	–	﹤0.01%	4659
2018 Q3	$297K	Hold	3,750	–	–	﹤0.01%	4723
2018 Q2	$263K	Sell	3,750 -100	-3%	-$7.19K	﹤0.01%	4850
2018 Q1	$269K	Sell	3,850 -175,100	-98%	-$12.1M	﹤0.01%	4839
2017 Q4	$12.4M	Buy	178,950 +132,100	+282%	+$8.91M	﹤0.01%	2288
2017 Q3	$3.17M	Sell	46,850 -144,150	-75%	-$9.11M	﹤0.01%	3570
2017 Q2	$13M	Buy	191,000 +160,650	+529%	+$10.5M	﹤0.01%	2302
2017 Q1	$1.89M	Sell	30,350 -15,900	-34%	-$926K	﹤0.01%	3797
2016 Q4	$2.53M	Buy	46,250 +14,550	+46%	+$826K	﹤0.01%	3637
2016 Q3	$2.08M	Buy	31,700 +15,950	+101%	+$1.04M	﹤0.01%	3799
2016 Q2	$951K	Buy	15,750 +1,000	+7%	+$58.1K	﹤0.01%	4225
2016 Q1	$831K	Sell	14,750 -46,050	-76%	-$2.77M	﹤0.01%	4233
2015 Q4	$4.13M	Buy	60,800 +9,000	+17%	+$590K	﹤0.01%	3010
2015 Q3	$3.3M	Buy	51,800 +22,700	+78%	+$1.49M	﹤0.01%	3280
2015 Q2	$1.85M	Buy	29,100 +600	+2%	+$41.1K	﹤0.01%	3899
2015 Q1	$1.95M	Sell	28,500 -247,600	-90%	-$17.2M	﹤0.01%	3801
2014 Q4	$19.4M	Sell	276,100 -374,500	-58%	-$26.8M	0.01%	1836
2014 Q3	$46.5M	Buy	650,600 +261,200	+67%	+$19.1M	0.01%	1120
2014 Q2	$28.9M	Buy	389,400 +155,700	+67%	+$11.3M	0.01%	1507
2014 Q1	$15.2M	Buy	233,700 +84,900	+57%	+$5.48M	0.01%	1995
2013 Q4	$8.83M	Buy	148,800 +69,100	+87%	+$3.75M	﹤0.01%	2468
2013 Q3	$4.14M	Sell	79,700 -11,300	-12%	-$568K	﹤0.01%	3144
2013 Q2	$4.3M	Buy	+91,000	New	+$4.63M	﹤0.01%	2895

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Goldman Sachs's AZN Position: Q1 2026 in Review

Goldman Sachs increased its AstraZeneca (AZN) stake by 47% in Q1 2026, buying an estimated $656M and bringing the position to 10,605,842 shares worth $2.09B. The position accounts for 0.24% of the portfolio, ranked #63.

Goldman Sachs first reported a position in AZN in Q2 2013 and has held it in 52 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Goldman Sachs held 10,605,842 shares of AstraZeneca worth $2.09B as of Q1 2026.
Goldman Sachs bought 3,400,181 AstraZeneca shares in Q1 2026, an estimated $656M.
AstraZeneca made up 0.24% of Goldman Sachs's portfolio in Q1 2026, its #63 holding.
Goldman Sachs first reported a position in AstraZeneca in Q2 2013 and has held it in 52 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.